Navigation Links
Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
Date:11/21/2011

e are encouraged by our findings that TTF therapy will find a critical role in the treatment of patients with recurrent GBM."

"The results of this long term follow up continue to validate the promise that NovoTTF™ therapy provides to the thousands of patients who suffer from recurrent GBM," said Asaf Danziger, CEO of Novocure. "We will continue to investigate the potential of this innovative treatment in other types of solid tumor cancers and look forward to sharing our results with the medical community in the future."

About Glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the most aggressive and deadly forms of cancer.

About the NovoTTF-100A System™

NovoTTF-100A System™ is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life without many of the side effects of chemotherapy. The NovoTTF-100A has received marketing approval in the US and is
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DEXILANT (dexlansoprazole) Product Information Updated Regarding Coadministration with Plavix (clopidogrel bisulfate)
2. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
3. Updated Hepatitis C Practice Guidelines Now Available from AASLD
4. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
5. Updated: Teikoku Pharma USA, Inc. and Verde Environmental Technologies, Inc. Announce Licensing Agreement for Pharmaceutical Disposal Technology
6. Questcor Provides Updated New Paid Prescription Trends
7. Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
8. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
9. Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
10. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
11. TPI Business and Development Profile Updated on OneMedDatabase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... used to develop, manufacture and sell enzymes and other ... enzyme industries, announced today that it will report its ... 2014 after market close on Thursday, August 14, 2014 ... 5:00 p.m. Eastern Time to discuss those results. ...
(Date:7/31/2014)... Indien, August 1, 2014 ... Inc. gaben heute bekannt, vor kurzem für ... zur Schmerzbehandlung nach chirurgischen Eingriffen eine kommerzielle ... der Europäischen Union und weiterer europäischer Länder ... und mit Ropivacain gefüllte OneDose ReadyfusOR später ...
(Date:7/31/2014)... Calif., July 31, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... ended July 4, 2014 of $20.0 million, a 10% ... of 2013. On a constant currency basis, revenues grew ... the second quarter of 2013.  The effect of foreign ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 2010 /PRNewswire-- Sangart, Inc., a global biopharmaceutical ... to enhance the perfusion and oxygenation of ischemic ... gas delivery, today announced that its investigational biopharmaceutical ... by the U.S. Food and Drug Administration (FDA) ...
... A new electronic health record (EHR) safety reporting ... not-for-profit organization composed of medical society and professional liability ... Network. EHRevent.org establishes a national system where ... related to the implementation and use of EHRs. ...
Cached Medicine Technology:Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 2Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 3New National Electronic Health Record Safety System Launched 2New National Electronic Health Record Safety System Launched 3New National Electronic Health Record Safety System Launched 4New National Electronic Health Record Safety System Launched 5New National Electronic Health Record Safety System Launched 6
(Date:8/2/2014)... According to the Girl Gets Ring System review ... for women. The book consists of dating tips and tricks ... book also teaches women how to deal with relationship ... its review that this book is divided into 10 chapters ... Story? ,     Chapter 2 – How A Traffic Light ...
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health ... settle the class action lawsuit filed October 24, ... 24-C-13-001041 MM, on behalf of thousands of women who allegedly ... According to The Baltimore Sun , the $190 ... a physician accused of sexual misconduct. , An investigation prompted ...
(Date:8/1/2014)... The successful development of C60F projects is of ... Automobile Co.,LTD. As early as the very beginning of ... excellent team to develop a comprehensive plan to carry ... The company’s vice president Liming Yang and some of ... the specific arrangement and the supervision of the project ...
(Date:8/1/2014)... of Medicine in St. Louis helps explain why brain ... more harmful than similar tumors in females. For example, ... twice as often in males, who suffer greater cognitive ... , The researchers found that retinoblastoma protein (RB), a ... active in male brain cells than in female brain ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2
... House ceremony next month, Thomas L. Kash, PhD, assistant professor ... for Alcohol Studies at the University of North Carolina at ... Career Award for Scientists and Engineers (PECASE). , This is ... science and engineering professionals in the early stages of their ...
... in the October 2011 issue of The FASEB ... "healthy" ingredient in red wine, stops breast cancer cells ... This discovery, made by a team of American and ... is able to counteract the malignant progression since it ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Sept. 28 ... advanced Alzheimer,s or other form of severe dementia will be shuttled ... months of life, a new U.S. study shows. The ... Depending on where a patient lives, as many as ...
... the British Journal of Sports Medicine * highlights the injury ... chance of a school player suffering an injury during a single ... research, could be as high as 90 per cent. The ... City University say there is an urgent need to inform children, ...
... with dementia can still make decisions in their everyday lives ... as their condition advances. This is one of the preliminary ... and Social Research Council (ESRC) into how married couples living ... study is investigating how couples make decisions over issues such ...
... dose of the hallucinogen psilocybin, the active ingredient in ... measureable personality change lasting at least a year in ... new study, according to the Johns Hopkins researchers who ... part of the personality known as openness, which includes ...
Cached Medicine News:Health News:UNC researcher to receive highest US honor for early career science professionals 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 3Health News:Academic issues warning on schoolboy rugby 2Health News:Living with dementia and making decisions 2Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa uncemented stem....
M2 cemented hip stem....
Medicine Products: